Published in Nat Rev Urol on February 21, 2012
Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy. Prostate Cancer Prostatic Dis (2012) 1.42
Prostate cancer: androgen deprivation causes EMT in the prostate. Nat Rev Urol (2011) 0.81
Prostate cancer: cabozantinib reduces pain and narcotic use in men with CRPC. Nat Rev Urol (2014) 0.78
Bladder cancer: aristolochic acid--one of the most potent carcinogens known to man. Nat Rev Urol (2013) 0.78
Prostate cancer: Visual estimation versus software fusion for MRI-targeted biopsy. Nat Rev Urol (2013) 0.77
Kidney cancer: predicting survival after targeted therapy for mRCC. Nat Rev Urol (2013) 0.77
Kidney cancer: bad news for personalized therapy. Nat Rev Urol (2012) 0.77
Kidney cancer: Metabolomics for targeted therapy. Nat Rev Urol (2012) 0.77
Bladder cancer: Pioglitazone increases risk of bladder cancer. Nat Rev Urol (2012) 0.76
Prostate cancer: metformin--the new wonder drug? Nat Rev Urol (2014) 0.76
Prostate cancer: Focal cryotherapy--results of a COLD search. Nat Rev Urol (2011) 0.75
Incontinence: novel grafting technique restores bladder function after spinal cord transection. Nat Rev Urol (2013) 0.75
Clinical trials: Combination therapy effective for treating male storage symptoms. Nat Rev Urol (2013) 0.75
Sexual medicine: Can pelvic measurements predict gender identity disorder? Nat Rev Urol (2012) 0.75
Sexual dysfunction: C. histolyticum collagenase effective against Peyronie. Nat Rev Urol (2012) 0.75
Urinary incontinence: Could two cups of coffee a day cause urinary incontinence in men? Nat Rev Urol (2013) 0.75
BPH: age not an issue for HoLEP. Nat Rev Urol (2013) 0.75
Infectious disease: Chlamydia-induced infertility. Nat Rev Urol (2013) 0.75
Paediatrics: antimicrobial prophylaxis for vesicoureteral reflux-where will the RIVUR study lead us? Nat Rev Urol (2014) 0.75
Paediatrics: no clear choice for imaging after first febrile UTI. Nat Rev Urol (2013) 0.75
Paediatric urology: cuff-only AUS for refractory neurogenic incontinence. Nat Rev Urol (2013) 0.75
Bladder cancer: faster recovery after radical cystectomy with alvimopan. Nat Rev Urol (2014) 0.75
Prostate cancer: two whole-blood RNA expression signatures for aggressive CRPC. Nat Rev Urol (2012) 0.75
Incontinence: OnabotulinumtoxinA safer than abobotulinumtoxinA for OAB. Nat Rev Urol (2013) 0.75
BPH: Hormone antagonists for two-pronged attack on BPH. Nat Rev Urol (2012) 0.75
Prostate cancer: Could an antimalarial drug delay the onset of CRPC? Nat Rev Urol (2013) 0.75
Bladder cancer: Getting into the right (urine) headspace. Nat Rev Urol (2013) 0.75
Prostate cancer: Non-O blood type is VTE risk factor after radical prostatectomy. Nat Rev Urol (2013) 0.75
Prostate cancer: Vitamin E and prostate cancer--what is the real risk? Nat Rev Urol (2011) 0.75
Bladder cancer: Replacing cystoscopies with FGFR3 urine assays. Nat Rev Urol (2012) 0.75
Prostate cancer: does a negative second biopsy give patients false hope? Nat Rev Urol (2013) 0.75
Prostate cancer: Heavy water labelling could be used to monitor progression of low-risk prostate cancer. Nat Rev Urol (2012) 0.75
Urinary tract infections: autophagy gene mutation confers protection against uropathogenic E. coli infection. Nat Rev Urol (2012) 0.75
Prostate cancer: TMPRSS2:ERG--the root of the problem? Nat Rev Urol (2013) 0.75
Can PDE5 inhibitors boost brain function? Nat Rev Urol (2013) 0.75
Infection: formalin needle disinfection reduces sepsis risk of prostate biopsy. Nat Rev Urol (2013) 0.75
Paediatric urology: invasive management needed for failed pyeloplasty? Nat Rev Urol (2013) 0.75
Prostate cancer: Prostate size can predict upgrading. Nat Rev Urol (2011) 0.75
Paediatrics: dipstick adequate for febrile UTI test. Nat Rev Urol (2014) 0.75
Clinical trials: mirabegron for treating OAB. Nat Rev Urol (2012) 0.75
Urinary tract infections: oral FimH inhibitors effective against UTI. Nat Rev Urol (2011) 0.75
Prostate cancer: who will win the CRPC drug race? Nat Rev Urol (2011) 0.75
Prostate cancer: prostatic swelling and shift upon HIFU. Nat Rev Urol (2013) 0.75
Transplantation: Urinary RNA test to predict kidney graft rejection. Nat Rev Urol (2013) 0.75
Prostate cancer: New light shed on the anticancer effects of zoledronic acid. Nat Rev Urol (2012) 0.75
Prostate cancer: What is the real IMPACT of BRCA1/BRCA2 mutation? Nat Rev Urol (2014) 0.75
Kidney cancer: Survival benefit of RCC vaccine. Nat Rev Urol (2012) 0.75
Regenerative medicine: Transplantable functional kidney built on a biocompatible scaffold. Nat Rev Urol (2013) 0.75
Prostate cancer: reducing IGF-1 levels unlikely to ProtecT against prostate cancer initiation. Nat Rev Urol (2011) 0.75
Male factor infertility: effects of ROS and vitamin E on sperm. Nat Rev Urol (2012) 0.75
Prostate cancer: the androgen receptor-a novel target for vaccines. Nat Rev Urol (2012) 0.75
Kidney cancer: Karakiewicz models are robust. Nat Rev Urol (2013) 0.75
Prostate cancer: Robotic versus laparoscopic RP. Nat Rev Urol (2012) 0.75
Prostate cancer: Magnetic particle thermotherapy for treating bone metastases. Nat Rev Urol (2013) 0.75
Kidney cancer: Low serum sodium linked to poor outcomes for patients with mRCC treated with targeted therapy. Nat Rev Urol (2013) 0.75
Prostate cancer: combined FEC-PET/MRI improves diagnostic accuracy. Nat Rev Urol (2014) 0.75
Male factor infertility: Asymptomatic testicular microlithiasis does not increase antisperm antibody production in infertile men. Nat Rev Urol (2012) 0.75
Male factor infertility: Melatonin could offer protection against testicular damage caused by a high-fat diet. Nat Rev Urol (2012) 0.75
Prostate cancer: Could a single blood test replace TRUS for predicting prostate cancer risk? Nat Rev Urol (2013) 0.75
Prostate cancer: Cardiovascular morbidity risk lower for ADT with GnRH antagonists than GnRH agonists. Nat Rev Urol (2013) 0.75
Paediatric urology: scoring system for testicular torsion. Nat Rev Urol (2012) 0.75
Prostate cancer: PET-CT for pelvic node staging. Nat Rev Urol (2011) 0.75
Bladder cancer: Potentially fewer minor complications with RARC than ORC but at what cost? Nat Rev Urol (2014) 0.75
Sexual dysfunction: Psychological inputs to sexual dysfunction. Nat Rev Urol (2012) 0.75
Prostate cancer: new class of drug that interferes with AR signalling. Nat Rev Urol (2013) 0.75
BPH: The hole-punch approach to treating LUTS. Nat Rev Urol (2012) 0.75
Prostate cancer: following the ethanol TRAIL to prostate cancer destruction. Nat Rev Urol (2012) 0.75
Prostate cancer: Ghrelin imaging probe specific for prostate cancer. Nat Rev Urol (2012) 0.75
The difference between men and women. Nat Rev Urol (2013) 0.75
Tipping the balance in favour of degarelix for ADT. Nat Rev Urol (2014) 0.75
Should we give metformin to all men with CRPC? Nat Rev Urol (2014) 0.75
Prostate cancer: Open vs laparoscopic vs robotic RP-the biggest study to date. Nat Rev Urol (2013) 0.75